Strengthening the health surveillance of marine mammals in the waters of metropolitan France by monitoring strandings

peer reviewedMonitoring the health status of marine mammals is a priority theme that France aims to develop with the other European Union Member States in the next two years, in the context of the Marine Strategy Framework Directive. With approximately 5,000 km of coastline and for nearly ten years, France has been recording an average of 2,000 strandings per year, which are monitored by the National Stranding Network, managed by Pelagis, the observatory for the conservation of marine mammals from La Rochelle University and the French National Center for Scientific Research. Since 1972, this network has successively evolved from spatial and temporal faunistic description to, nowadays, the detection of major causes of mortality. It now aims to carry out epidemiological studies on a population scale. Thus, a strategy to strengthen the monitoring of marine mammals’ health status based on stranding data has been developed. This strategy will allow for a more accurate detection of anthropogenic cause of death as well as those of natural origin. It will allow the monitoring of time trends and geographical differences of diseases associated with conservation and public health issues while ensuring the early detection of emerging and/or zoonotic diseases of importance. It will also allow a better assessment of the consequences of human activities on these animal populations and on the environment. Thus, this strategy is fully in line with the “One Health” approach which implies an integrated vision of public, animal and environmental health. It is broken down into four surveillance modalities: (1) general event-based surveillance (GES); (2) programmed surveillance (PS); (3) specific event-based surveillance (SES); (4) and in the longer term, syndromic surveillance (SyS). This article describes the French strategy as well as these different surveillance modalities, the levels of examinations and the associated sampling protocols and finally, the method of standardisation of the data collected. The objective is to present the strategy developed at the French level in order to integrate it into a future strategy shared at the European level to standardise practices and especially complementary analysis, necessary for a better evaluation of the health status of these mobile marine species

Abstract P2-05-08: Combined neoadjuvant iniparib and carboplatin in locally advanced or metastatic canine mammary tumors (MT) to support human clinical studies

Abstract INTRODUCTION Among breast cancers, the triple negative subtype (negative for hormone receptors and not overexpressing HER2) has the worst prognosis and its response to Iniparib has been investigated in clinical trials. Further investigations are needed to optimize drug schedule and patient selection criteria. Iniparib antitumor mechanism is not completely understood, as well as iniparib diffusion kinetic into tumoral tissues. We address these questions in spontaneous canine invasive mammary carcinomas, which are a good model for this cancer subtype (Ibisch et al., World Veterinary Cancer Congress 2012), in a neoadjuvant setting. To our knowledge, this is the first study of iniparib administration in cancer-bearing dogs. MATERIAL AND METHODS Twenty female dogs with spontaneous MT with malignant criteria (tumor size, speed of growth, ulceration, relapse, or metastasis) were included. All tumors were described as rapidly growing. Dogs received a first infusion of iniparib at day 0 and a combination of carboplatin and iniparib at day 7. Biological materials (tumor biopsies and blood) were collected before and 5 minutes after iniparib infusion for pharmacokinetic and metabolism studies. Tumor response was evaluated by caliper measurements and histopathological analysis of mammary tumors and draining lymph nodes. A chain mastectomy was performed 3 or 4 weeks later. Histological records included the subtype of carcinoma (WHO 1999), Elston &amp; Ellis grade, presence of emboli, lymph node metastasis and IHC stainings using ER, PR, Her2 (scored according to Wolff et al.2007), CK5/6, EGF-R and Ki67. Intensity of necrosis and apoptosis was evaluated using PAS coloration and immunohistochemistry for caspase 3, at DO on tumor biopsies and at surgery. Toxicity of the protocol was evaluated and its efficiency on invasive carcinomas was compared to surgery alone (control group of 27 female dogs with invasive mammary carcinomas treated by chain mastectomy alone). RESULTS Treated and control groups shared similar features concerning animal breeds, age, neutering status and tumor location. 75% of the treated MT were malignant. Necrosis and apoptosis were significantly increased in respectively 63 and 56% of iniparib treated tumors. Clinical evidence of toxicity was minimal (15% of dogs with nausea, 60% with transient polyuria-polydipsia). Tumor stabilization was observed before surgery in all dogs but one. Median survival has not been reached. CONCLUSION Iniparib at 35mg/kg combined with carboplatin at 300 mg/m2 seemed well tolerated in this study and deserves further investigations. The degree of necrosis and apoptosis in the treated tumors can be evaluated with these techniques. Iniparib pharmacokinetic and metabolism studies in cancer-bearing dogs are ongoing. Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr P2-05-08.</jats:p

Cancer : a missing link in ecosystem functioning ?

Cancer is a disease that affects the majority of metazoan species and, before directly causing host death, is likely to influence the competitive abilities of individuals, their susceptibility to pathogens, their vulnerability to predators, and their ability to disperse. Despite the potential importance of these ecological impacts, cancer is rarely incorporated into model ecosystems. We describe here the diversity of ways in which oncogenic phenomena, from precancerous lesions to generalized metastatic cancers, may affect ecological processes that govern biotic interactions. We argue that oncogenic phenomena, despite their complexity, can have significant and sometimes predictable ecological consequences. Our aim is to provide a new perspective on the ecological and evolutionary significance of cancer in wildlife, and to stimulate research on this topic

Ecology and evolution of cancer

Neoplasia has been recorded in the vast majority of metazoans. The frequent occurrence of cancer in multicellular organisms suggests that neoplasia, similar to pathogens/parasites, may have a significant negative impact on host fitness in the wild. This is supported by the fact that wildlife cancers have recently been shown to result in significantly increased levels of mortality and concomitant reduction in fitness. By thorough searches of the available literature we provide a comprehensive and an updated list of cancer prevalence and etiology in the wild. We were, however, unable to find data on nontransmissible cancer prevalence in invertebrates and consequently this chapter focuses on cancer in wild vertebrates. Although single cases of cancer are frequently encountered in the wildlife, we were only able to retrieve robust data on cancer prevalence for 31 vertebrate species (12 fish, 3 amphibians, 2 reptiles, 2 birds, and 12 mammals). Cancer prevalence among these vertebrates ranged from as low as 0.2% observed in Canada geese (Branta canadensis) to more than 50% recorded in both Santa Catalina Island foxes (Urocyon littoralis catalinae) and Cape mountain zebras (Equus zebra zebra). The high prevalence recorded in some vertebrates strongly suggests that cancer in wildlife may indeed carry significant fitness costs. In spite of this, the low number of published comprehensive studies clearly shows that so far cancer in wildlife has received insufficient attention by biologists. We hope that this chapter will act as a catalyst for further studies focusing on the impact of cancer in wild animals. The chapter additionally compares cancer recorded in French zoological parks to those obtained at other zoological parks. Finally, we provide an updated list of cancer recorded as single cases in the wild, as well as in captive animals

Animal behaviour and cancer

Scientists are increasingly coming to realize that oncogenic phenomena are both frequent and detrimental for animals, and must therefore be taken into account when studying the biology of wildlife species and ecosystem functioning. Here, we argue that several behaviours that are routine in an individual\u27s life can be associated with cancer risks, or conversely prevent/cure malignancies and/or alleviate their detrimental consequences for fitness. Although such behaviours are theoretically expected to be targets for natural selection, little attention has been devoted to explore how they influence animal behaviour. This essay provides a summary of these issues as well as an overview of the possibilities offered by this research topic, including possible applications for cancer prevention and treatments in humans

Rare and unique adaptations to cancer in domesticated species: An untapped resource?

Strong and ongoing artificial selection in domestic animals has resulted in amazing phenotypic responses that benefit humans, but often at a cost to an animal's health, and problems related to inbreeding depression, including a higher incidence of cancer. Despite high rates of cancer in domesticated species, little attention has been devoted to exploring the hypothesis that persistent artificial selection may also favour the evolution of compensatory anticancer defences. Indeed, there is evidence for effective anti-cancer defences found in several domesticated species associated with different cancer types. We also suggest that artificial selection can favour the "domestication" of inherited oncogenic mutations in rare instances, retaining those associated to late and/or less aggressive cancers, and that by studying these seemingly rare anticancer adaptations, novel cancer treatments may be found